{"id":34984,"date":"2025-06-10T17:40:51","date_gmt":"2025-06-10T09:40:51","guid":{"rendered":"https:\/\/flcube.com\/?p=34984"},"modified":"2025-06-10T17:40:52","modified_gmt":"2025-06-10T09:40:52","slug":"immuneonco-appoints-zhuli-wu-as-chief-medical-officer-to-lead-clinical-strategy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34984","title":{"rendered":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy"},"content":{"rendered":"\n

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541<\/a>) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.<\/p>\n\n\n\n

Leadership and Experience<\/strong>
With over 13 years of specialization in hematology and immuno-oncology drug development, Ms. Wu has held leadership roles at Janssen Pharmaceuticals, Roche, and Shanghai Fosun Pharma, where she served as Senior Vice President of R&D and China CMO for Oncology. She has led over 40 Investigational New Drug (IND) applications and spearheaded 5 New Drug Applications (NDAs), resulting in 3 approvals and 3 Breakthrough Therapy designations.<\/p>\n\n\n\n

Key Achievements<\/strong>
Ms. Wu played a pivotal role in accelerating the approval of the MEK inhibitor lumosertib, which is China\u2019s first-in-class treatment for histiocytic disorders\/tumors and pediatric neurofibromatosis type 1-related plexiform neurofibromas, addressing significant unmet medical needs.<\/p>\n\n\n\n

Industry Involvement<\/strong>
In addition to her industry leadership, Ms. Wu is an active member of the Chinese Society of Clinical Oncology (CSCO) Clinical Trial Committee and the China Pharmaceutical Innovation and Research Development Association (PhIRDA) Oncology Drug Clinical Research Committee.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as…<\/p>\n","protected":false},"author":1,"featured_media":34985,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1028,229],"class_list":["post-34984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-hkg-1541","tag-immuneonco-biopharmaceuticals"],"yoast_head":"\nImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34984\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy\" \/>\n<meta property=\"og:description\" content=\"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34984\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T09:40:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-10T09:40:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy\",\"datePublished\":\"2025-06-10T09:40:51+00:00\",\"dateModified\":\"2025-06-10T09:40:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1012.webp\",\"keywords\":[\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34984#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34984\",\"name\":\"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1012.webp\",\"datePublished\":\"2025-06-10T09:40:51+00:00\",\"dateModified\":\"2025-06-10T09:40:52+00:00\",\"description\":\"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34984\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1012.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1012.webp\",\"width\":1080,\"height\":608,\"caption\":\"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34984#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy - Insight, China's Pharmaceutical Industry","description":"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34984","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy","og_description":"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.","og_url":"https:\/\/flcube.com\/?p=34984","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-10T09:40:51+00:00","article_modified_time":"2025-06-10T09:40:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34984#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34984"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy","datePublished":"2025-06-10T09:40:51+00:00","dateModified":"2025-06-10T09:40:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34984"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34984#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","keywords":["HKG: 1541","ImmuneOnco Biopharmaceuticals"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34984#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34984","url":"https:\/\/flcube.com\/?p=34984","name":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34984#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34984#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","datePublished":"2025-06-10T09:40:51+00:00","dateModified":"2025-06-10T09:40:52+00:00","description":"China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34984#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34984"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34984#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","width":1080,"height":608,"caption":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34984#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1012.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34984"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34984\/revisions"}],"predecessor-version":[{"id":34986,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34984\/revisions\/34986"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34985"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}